Seoul National University will participate in CES 2022 with 10 prospective unicorns
LAS VEGAS, Jan. 3, 2022 /PRNewswire/ -- Seoul National University (President Se-Jung OH) will dispatch the "SNU Exhibition Group" to the world's largest IT and home appliance exhibition (CES) 2022 to be held in Las Vegas for four days from January 5th of the new year, and showcase representative startups and core start-up technologies. Seoul...
EVOSONICS will launch 12 products including Sleep tech Sound pillows at CES 2022
WONJU, South Korea, Jan. 3, 2022 /PRNewswire/ -- EVOSONICS (CEO Jason Choi), a sound vibration-based healthcare company, announced on the 30th that it will submit sleep tech devices, rehabilitation devices and obesity management devices through CES2022 in Las Vegas, USA, from January 5, 2022. EVOSONICS will launch 12 products including Sleep tech Sound pillows at CES...
Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD
NEWARK, Del. and NANJING, China, Jan. 3, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Dr. Anthony Yeh to the position of Chief Strategy Officer and Head of China business development (BD), where he will lead corporate strategy, China BD, and capital fundraising. He will report to Dr. Mingjiu...
Sihuan Pharmaceutical (0460.HK): Sunshine Life Insurance Leads Investment in Xuanzhu Biopharm
HONG KONG, Jan. 3, 2022 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460) is pleased to announce that, its subsidiary Xuanzhu Biopharmaceutical Co., Ltd.( "Xuanzhu Biopharm") has completed a Series B financing of RMB610.5 million on December 31, 2021. This round...
Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus
- Ritonavir oral tablet annual production capacity has been expanded to 100 million tablets and can be further rapidly expanded based on market demand - ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection - ASC11 is an oral direct-acting antiviral drug candidate targeting 3-chymotrypsin like protease (3CLpro), combined...
CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration
SUZHOU, China, Jan. 3, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the investigational new drug (IND) application of CS5001, a potential global best-in-class antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) has received a STUDY MAY...
Pulnovo Medical Announced Results From PADN-CFDA Pivotal Trial For The Treatment Of Pulmonary Arterial Hypertension (PAH) Meet The Efficacy Primary Endpoint
SHANGHAI, Jan. 1, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pioneer in treatment for cardiopulmonary disease, today announced the positive results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study, being the first global completed pulmonary hypertension treatment device RCT study. PADN is an innovative radiofrequency ablation technique in treating PH, was recognized as a CFDA innovative medical device...
TODOC to Introduce High-Performance and Low-Cost Artificial Cochlear Implant ‘SULLIVAN’ at CES 2022
SEOUL, South Korea, Jan. 1, 2022 /PRNewswire/ -- TODOC (CEO Min Gyu-sik) will introduce their artificial cochlear implant 'SULLIVAN' at the "CES 2022" which will be held in Las Vegas on January 5, 2022 (local time), after it was selected in the 'Top 10 Korean Products of CES 2022.' Organized by the ETNews (Electronic Times Internet), "Top 10...
I-Mab Announces Upcoming Participation at January Conferences
SHANGHAI and GAITHERSBURG, MD., Dec. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences in January 2022. Details of the conferences and management presentation are as follows: 40th Annual J.P. Morgan Healthcare Conference Presentation: Tuesday, January 11, 2022,...
GBB Closed the A Round Financing with Newly Joined FutureX Capital
HONG KONG, Dec. 31, 2021 /PRNewswire/ -- Great Bay Bio (GBB), an AI-enabled biotechnology company, announces the participation of FutureX Capital in its Series A round fundraising. Great Bay Bio finished A round financing of near USD 10 million on December 1, 2021. The investors include Promixa Ventures, GL Ventures, Alibaba Entrepreneurs Fund, Alon Capital and FutureX Capital....
